Zymeworks Inc. (ZYME) Monday said the Food and Drug Administration (FDA) has cleared the investigational new drug application for ZW171 to treat mesothelin (MSLN)-expressing cancers.
The company plans to file applications with other regulators seeking permission for clinical studies of ZW171 in the second half of 2024.
ZW171, a bispecific antibody, is designed to enable T cell-mediated tumor cell killing through simultaneous binding to the extracellular domain of MSLN protein on tumor cells and the engagement of CD3 on T cells. Moderate to high membranous MSLN expression is often seen in ovarian cancer, non-small cell lung cancer, mesothelioma and other cancers.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.